A DNMT3A Mutation Common in AML Exhibits Dominant-negative Effects in Murine ES Cells
Overview
Affiliations
Somatic heterozygous mutations of the DNA methyltransferase gene DNMT3A occur frequently in acute myeloid leukemia and other hematological malignancies, with the majority (∼60%) of mutations affecting a single amino acid, Arg882 (R882), in the catalytic domain. Although the mutations impair DNMT3A catalytic activity in vitro, their effects on DNA methylation in cells have not been explored. Here, we show that exogenously expressed mouse Dnmt3a proteins harboring the corresponding R878 mutations largely fail to mediate DNA methylation in murine embryonic stem (ES) cells but are capable of interacting with wild-type Dnmt3a and Dnmt3b. Coexpression of the Dnmt3a R878H (histidine) mutant protein results in inhibition of the ability of wild-type Dnmt3a and Dnmt3b to methylate DNA in murine ES cells. Furthermore, expression of Dnmt3a R878H in ES cells containing endogenous Dnmt3a or Dnmt3b induces hypomethylation. These results suggest that the DNMT3A R882 mutations, in addition to being hypomorphic, have dominant-negative effects.
Using human disease mutations to understand de novo DNA methyltransferase function.
Rolls W, Wilson M, Sproul D Biochem Soc Trans. 2024; 52(5):2059-2075.
PMID: 39446312 PMC: 11555716. DOI: 10.1042/BST20231017.
Clonal hematopoiesis and hematological malignancy.
Dunn W, McLoughlin M, Vassiliou G J Clin Invest. 2024; 134(19).
PMID: 39352393 PMC: 11444162. DOI: 10.1172/JCI180065.
Davletgildeeva A, Kuznetsov N Biomolecules. 2024; 14(9).
PMID: 39334883 PMC: 11430729. DOI: 10.3390/biom14091117.
Rauch P, Gopakumar J, Silver A, Nachun D, Ahmad H, McConkey M Nat Cardiovasc Res. 2024; 2(9):805-818.
PMID: 39196062 DOI: 10.1038/s44161-023-00326-7.
Hardikar S, Ren R, Ying Z, Zhou J, Horton J, Bramble M Sci Adv. 2024; 10(34):eadr0036.
PMID: 39178265 PMC: 11343032. DOI: 10.1126/sciadv.adr0036.